Enclomiphene: raising your own testosterone, with a catch

Standard testosterone replacement therapy (TRT) has a well-known trade-off: giving the body testosterone from outside shuts down its own production. The brain reads the high testosterone, dials down LH and FSH, and the testicles — no longer signaled — shrink and stop making sperm. For a man who wants his testosterone up but also wants to preserve fertility, that’s a real problem. Enclomiphene is the drug built to solve exactly that, and understanding why it’s interesting means understanding why, despite working, it never got approved.

Enclomiphene is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM). Its whole design is to raise your own testosterone rather than replace it — and that different mechanism is both its appeal and, ultimately, the source of its regulatory catch.

The mechanism — restoration, not replacement

Testosterone and estrogen feed back on the pituitary to suppress the hormones (LH and FSH) that drive the testicles. Enclomiphene blocks estrogen receptors at the pituitary, so the brain no longer “sees” the estrogen brake. It responds by increasing LH and FSH, which in turn tell the testicles to make more of their own testosterone — and, crucially, to keep making sperm. The framing that captures it: restoration of the natural axis rather than external replacement. That’s the opposite of what TRT does to fertility.

What the evidence shows

The trial evidence for the mechanism is actually decent — this is the strongest part of the story.

• Wiehle 2014 (a phase II RCT in Fertility & Sterility) compared enclomiphene to topical testosterone gel. Enclomiphene raised testosterone to a comparable degree — but while the gel suppressed LH, FSH, and sperm production, enclomiphene maintained them. The core promise held up: higher testosterone without sacrificing fertility.
• Kim 2016 reported the phase III program (the ZA-304 and ZA-305 trials) in BJU International, in obese hypogonadal men. The results were consistent: enclomiphene raised testosterone while preserving LH, FSH, and sperm concentration, where testosterone gel suppressed them. Two trials pointing the same way is a reasonable evidence base for the hormonal claim — grade B.

So on its own terms, enclomiphene does what it says: it raises endogenous testosterone and preserves the reproductive axis. Where the story turns is regulation.

The catch — it isn’t FDA-approved

This is the part that has to be stated plainly. Enclomiphene, developed as Androxal by Repros Therapeutics, failed to gain FDA approval. The trials met their hormonal endpoints — testosterone went up, sperm was preserved — but regulators took the position that raising testosterone numbers alone was not sufficient without a clear demonstration of clinical benefit and a settled path on how the drug should be studied and used. Androxal never made it to market.

The practical consequence: there is no FDA-approved enclomiphene product. Every current use is off-label and compounded. That doesn’t make it fraudulent — the underlying trials are real and the mechanism is sound — but it does mean you’re relying on a compounding pharmacy rather than a regulated manufactured drug, without the FDA’s sign-off on efficacy, quality, and labeling that approval would provide. Grade the regulatory reality honestly: the science is B; the “is this an approved medicine?” answer is a flat no.

Who it’s for, and the monitoring it needs

Enclomiphene makes the most sense for a specific person: a hypogonadal man who wants to raise testosterone while preserving fertility and testicular function — a younger man planning to have children, or anyone for whom the fertility-suppressing effect of TRT is a dealbreaker. For that person, and with a clinician, it’s a legitimate conversation.

If pursued, it’s a monitored one: baseline and follow-up testosterone, LH, FSH, and estradiol, and a semen analysis if fertility is the actual goal, to confirm the drug is doing what’s intended. It’s a men’s-health / urology / endocrinology decision, not a self-order.

The honest bottom line

Enclomiphene is a genuinely elegant idea backed by real trials: it raises your own testosterone and, unlike TRT, keeps your fertility intact. The catch is not subtle — it isn’t FDA-approved, the brand version failed, and it’s available only compounded and off-label. That combination lands it squarely in “context, not verdict” territory: worth discussing with a clinician if fertility preservation genuinely matters to you and you understand what off-label-and-compounded means, but not a settled, approved therapy — and emphatically not something to source from the “research chemical” gray market that has grown up around it.